Further, daratumumab (anti-CD38) systemic treatment reduced Tregs and expanded antitumor T-cell subsets in a patient-derived xenograft (PDX) CLL mouse model, suggesting that daratumumab provoked a potent antitumor response (59). This evidence concerns the gene CD38 and B-cell chronic lymphocytic leukemia.